CT in immunotherapy by imaging of tumor-infiltratingTcells
暂无分享,去创建一个
Xiaotu Ma | Fan Wang | Zhichen Sun | Jiyun Shi | Q. Luo | Yu Gao | Hannan Gao | Chuanhui Han | Yining Sun | Yue Yu
[1] L. Pearce,et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate , 2022, Journal for ImmunoTherapy of Cancer.
[2] S. Gambhir,et al. Whole-body PET Imaging of T-cell Response to Glioblastoma , 2021, Clinical Cancer Research.
[3] G. Hospers,et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[4] N. Devoogdt,et al. Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade , 2021, The Journal of Nuclear Medicine.
[5] Yakun Wan,et al. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.
[6] M. Lenardo,et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.
[7] Zhichen Sun,et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control , 2019, Nature Communications.
[8] Y. Nishimura,et al. Possible Biomarkers for Cancer Immunotherapy , 2019, Cancers.
[9] G. Ren,et al. Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy. , 2019, Cancer research.
[10] Q. Fu,et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis , 2019, Oncoimmunology.
[11] R. Herbst,et al. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes , 2019, Clinical Cancer Research.
[12] R. Weinberg,et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells , 2017, The Journal of experimental medicine.
[13] Hannah C. Beird,et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma , 2017, npj Genomic Medicine.
[14] Zhuxian Zhou,et al. Molecular imaging of the tumor microenvironment☆ , 2017, Advanced drug delivery reviews.
[15] T. Daemen,et al. Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging , 2017, Oncoimmunology.
[16] A. Rudensky,et al. An essential role for IL-2 receptor in regulatory T cell function , 2016, Nature Immunology.
[17] A. Ribas,et al. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.
[18] R. Ferris. Immunology and Immunotherapy of Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Tavaré,et al. Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies , 2015, The Journal of Nuclear Medicine.
[20] J. Wolchok,et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. , 2014, Cancer treatment reviews.
[21] A. Schmid,et al. In Vivo Tracking of Th1 Cells by PET Reveals Quantitative and Temporal Distribution and Specific Homing in Lymphatic Tissue , 2014, Journal of Nuclear Medicine.
[22] R. Tavaré,et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo , 2014, Proceedings of the National Academy of Sciences.
[23] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[24] T. Gajewski,et al. Cancer immunotherapy , 2012, Molecular oncology.
[25] J. Luketich,et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. , 2011, The Journal of surgical research.
[26] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[27] A. Signore,et al. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. , 2010, Nuclear medicine and biology.
[28] T. Malek,et al. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.
[29] S. Mather,et al. Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes , 2009, Molecular Imaging and Biology.
[30] Hans W. Nijman,et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer , 2008, Cancer Immunology, Immunotherapy.
[31] A. Grossman,et al. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[32] R. Weissleder,et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy , 2007, Proceedings of the National Academy of Sciences.
[33] C. June,et al. Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.
[34] K. Garcia,et al. Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.
[35] K. Garcia,et al. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. , 2005, Science.
[36] S. Calvieri,et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] H. Lyerly,et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] A. Lanzavecchia. Identifying strategies for immune intervention. , 1993, Science.